-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

Benzinga·10/09/2026 11:36:02
HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.